Firebrick Pharma (ASX:FRE) said Tuesday that the results of the first phase 3 clinical trial of its Nasodine nasal spray support the product's efficacy as a potential treatment for the common cold, especially when used early in the illness.
Based on the results, Nasodine 0.5% povidone-iodine nasal spray effectively reduced cold severity, improving quality of life scores, and delivered a 40% greater benefit than saline when used within 24 hours of symptom onset, according to a Tuesday filing with the Australian bourse.
Results, which were published in a peer-reviewed journal, also showed Nasodine to be safe and well-tolerated.
The randomized, double-blind study was conducted on 260 adults who received either Nasodine or a matching saline nasal spray.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.